UNSPSC 51295302: Eprovafen

This classification denotes a lipooxygenase inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4C9310B127. European Medicines Agency schedules Eprovafen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06587MIG. Eprovafen generally arises in the molecular formula C18H22O2S. The term EPROVAFEN is an International Non-Proprietary Name or INN. EPROVAFEN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule eprovafen under HS 29349990 and SITC 51579. As of Q4 2014, EPROVAFEN remains the US FDA Preferred Term for this commodity. Eprovafen bears US NLM identifiers UMLS ID C1880543 and NCI Concept Code C65521. SMILES: s1c(CCCCC(=O)O)ccc1CCCc1ccccc1.

UNSPSC 51295302 Eprovafen, a Commodity code, encompasses pharmaceutical products and related medical supplies that state and local governments procure for community health, public health emergency response, and institutional healthcare delivery. Recent solicitations show state and local buyers acquiring naloxone and drug deactivation systems for overdose response, generic pharmaceuticals and over-the-counter products for multi-jurisdictional health systems, and direct-to-manufacturer prescription programs to manage pharmacy costs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local participants across multiple states including Oregon). The code reflects both urgent public-health procurement—such as naloxone for overdose intervention—and routine institutional pharmaceutical supply management through established wholesale distribution networks.

Geographic activity appears concentrated in the Southeast and Upper Midwest, with recent solicitations posted from Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB 60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription models outside traditional pharmacy benefit manager arrangements; and MMCAP's RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to participating state and local facilities. Vendors responding to this code must typically meet FDA and cGMP compliance, maintain insurance coverage including commercial general liability and professional liability, provide EDI capability, and accept administrative fees or performance-based pricing models tied to volume and service metrics.